Health ❯ Healthcare ❯ Clinical Research

Drug Development

Clinical Trials Eli Lilly Phase 2 Trials Alzheimer's Treatments Regulatory Approval Lecanemab Immunotherapy Trials Phase 3 Trials GSK Innovations LENZ Therapeutics Therapeutic Innovations Cardiovascular Disease Antibody-Drug Conjugates (ADCs) Teplizumab Trials Biologic Drugs Orforglipron Pediatric Medicine Therapeutic Evaluation Gilead Sciences Tirzepatide Efficacy Regulatory Affairs Antisense Oligonucleotides Phase I/II Trials Medpace Holdings, Inc. Alzheimer's Disease Therapies Innovative Therapies Efficacy Studies Antiviral Candidates Oral Medications Comparative Effectiveness Therapeutics Antiviral Research Antimicrobial Resistance Strategies

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

A UCL mouse study ties maze memory deficits to scrambled hippocampal replay during rest.

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

EMA Committee Recommends EU Approval for First Oral Postpartum Depression Treatment

Antibiotic Energy Drain Found to Accelerate Bacterial Resistance